<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549832</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17300204</org_study_id>
    <nct_id>NCT03549832</nct_id>
  </id_info>
  <brief_title>Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure</brief_title>
  <official_title>Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin Versus Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin in the Management of Hepatitis C Patients Fauilre to Prior Sofosbuvir/ Daclatasvir (An Open-labeled Randomized Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those
      patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir
      /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/
      paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to
      prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCV management with new DAAs is now promising. However, many cases reporting treatment
      failure either non-responder or relapse to HCV treatment with Sofosbuvir/ Daclatasvir.
      retreat those patients is challenging. So, we aimed to Study the efficacy and safety of
      Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/
      paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to
      prior Sofosbuvir/ Daclatasvir regimens in a multicenter open-labeled randomized trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoint was the achievement of SVR at week 12 (SVR12) post-treatment. The potential adverse events were evaluated in each visit for the development of adverse events or any significant interactions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HCV Coinfection</condition>
  <arm_group>
    <arm_group_label>sof/sim/dac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sof/omb/parit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg oral pills</description>
    <arm_group_label>sof/omb/parit</arm_group_label>
    <arm_group_label>sof/sim/dac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir 150 mg oral pills</description>
    <arm_group_label>sof/sim/dac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Daclatasvir 60 mg oral pills</description>
    <arm_group_label>sof/sim/dac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 200 mg oral pills</description>
    <arm_group_label>sof/omb/parit</arm_group_label>
    <arm_group_label>sof/sim/dac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>Ombitasvir/paritaprevir/ritonavir oral pills</description>
    <arm_group_label>sof/omb/parit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with proven CHC genotype 4

          -  18 years old or more,

          -  prior HCV treatment failure to sofosbuvir /daclatasvir

          -  compensated liver disease.

        Exclusion Criteria:

          -  Patients with combined HCV/HBV co-infection, hepatocellular carcinoma (HCC),
             decompensated liver cirrhosis (Child-Pugh score above 6), and non-genotype 4 were
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Mekky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut University Hopsital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015 Nov;22(11):861-70. doi: 10.1111/jvh.12422. Epub 2015 Jun 17. Review.</citation>
    <PMID>26083155</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Abdelsabour Mekky</investigator_full_name>
    <investigator_title>Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>DAAs</keyword>
  <keyword>Non-responder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

